Genmab to Present at Morgan Stanley 16th Annual Global Healthcare Conference
September 06 2018 - 9:00AM
Genmab to Present at Morgan Stanley 16th Annual Global Healthcare
Conference
Media Release Copenhagen, Denmark;
September 6, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced
today that its CEO, Jan van de Winkel, Ph.D., will give a company
update at the Morgan Stanley 16th Annual Global Healthcare
Conference in New York, New York at 2:15 PM EDT / 8:15 PM CEST on
September 12, 2018. A webcast of the update, which
will include brief opening remarks followed by a
question-and-answer session, will be available on Genmab’s website
at http://ir.genmab.com/events.cfm.
About Genmab Genmab is a publicly traded,
international biotechnology company specializing in the creation
and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two
approved antibodies, DARZALEX® (daratumumab) for the treatment of
certain multiple myeloma indications, and Arzerra® (ofatumumab) for
the treatment of certain chronic lymphocytic leukemia
indications. Daratumumab is in clinical development for
additional multiple myeloma indications and other blood
cancers. A subcutaneous formulation of ofatumumab is in
development for relapsing multiple sclerosis. Genmab also has
a broad clinical and pre-clinical product pipeline. Genmab's
technology base consists of validated and proprietary next
generation antibody technologies - the DuoBody® platform for
generation of bispecific antibodies, and the HexaBody® platform
which creates effector function enhanced antibodies. The
company intends to leverage these technologies to create
opportunities for full or co-ownership of future products. Genmab
has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations
& CommunicationT: +45 33 44 77 20; M: +45 25 12 62 60; E:
rcg@genmab.com This Media Release contains forward looking
statements. The words “believe”, “expect”, “anticipate”, “intend”
and “plan” and similar expressions identify forward looking
statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual
results or performance to differ materially include, among others,
risks associated with pre-clinical and clinical development of
products, uncertainties related to the outcome and conduct of
clinical trials including unforeseen safety issues, uncertainties
related to product manufacturing, the lack of market acceptance of
our products, our inability to manage growth, the competitive
environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our
products obsolete, and other factors. For a further discussion of
these risks, please refer to the risk management sections in
Genmab’s most recent financial reports, which are available on
www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Media Release nor to
confirm such statements to reflect subsequent events or
circumstances after the date made or in relation to actual results,
unless required by law. Genmab A/S and/or its subsidiaries own the
following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in
combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®;
DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody
in combination with the HexaBody logo®; and UniBody®. Arzerra® is a
trademark of Novartis AG or its affiliates. DARZALEX® is a
trademark of Janssen Pharmaceutica NV.
Media Release no. 06CVR no. 2102 3884LEI Code
529900MTJPDPE4MHJ122
Genmab A/SKalvebod Brygge 431560 Copenhagen VDenmark
- i06_180906_MR_Morgan Stanley